Trav3d-3 Inhibitors
Trav3d-3 inhibitors are a class of chemical compounds designed to target and modulate the activity of the Trav3d-3 protein or receptor. These inhibitors typically function by binding directly to the active site of the Trav3d-3 protein, thereby preventing its interaction with natural substrates or other biological molecules. In some cases, Trav3d-3 inhibitors may also bind to allosteric sites, which are regions distinct from the active site. By binding to these allosteric sites, the inhibitors induce conformational changes in the protein structure, ultimately reducing or inhibiting its function. These inhibitors rely on a range of non-covalent interactions to achieve specificity and stability in their binding, including hydrogen bonding, hydrophobic interactions, ionic interactions, and van der Waals forces. The effectiveness of the inhibition depends largely on how well these inhibitors fit within the Trav3d-3 binding pocket and their ability to form stable interactions with key residues in the protein.
Structurally, Trav3d-3 inhibitors exhibit significant diversity, with their designs often tailored to maximize interaction with the specific structural features of the Trav3d-3 protein. Common structural motifs in these inhibitors include aromatic rings, heterocyclic cores, and various functional groups such as hydroxyl, amine, or carboxyl groups. These chemical features contribute to the inhibitor's binding affinity by enabling interactions with polar and non-polar regions of the Trav3d-3 protein. The overall size, shape, and flexibility of the inhibitor molecule are also critical factors in determining its binding strength and selectivity. Additionally, the physicochemical properties of Trav3d-3 inhibitors-such as their molecular weight, solubility, and lipophilicity-are important considerations in their design, as they influence not only the inhibitor's ability to interact with the Trav3d-3 protein but also its behavior in different biological environments. By carefully tuning these properties, scientists can create inhibitors that effectively block Trav3d-3 function while maintaining stability and solubility in various conditions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which could inhibit Trav3d-3 by blocking its phosphorylation-dependent activation assuming Trav3d-3 activity is regulated by phosphorylation as is common in signaling proteins. | ||||||
GW 5074 | 220904-83-6 | sc-200639 sc-200639A | 5 mg 25 mg | $106.00 $417.00 | 10 | |
GW5074 is a Raf kinase inhibitor and could inhibit Trav3d-3 by disrupting the MAPK/ERK signaling pathway, which is integral to various cellular processes, assuming Trav3d-3 is downstream or part of this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3 kinase inhibitor, which could inhibit Trav3d-3 by preventing activation of the AKT signaling pathway, often involved in survival and proliferation, assuming Trav3d-3 plays a role in or is modulated by this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which could inhibit Trav3d-3 by blocking the MEK/ERK signaling pathway, assuming Trav3d-3 is associated with this pathway or its downstream effects. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor and could inhibit Trav3d-3 by reducing the activity of the mTOR pathway, which regulates cell growth and metabolism, assuming Trav3d-3 is involved in or downstream of this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor, which could inhibit Trav3d-3 by preventing the activation of the p38 signaling pathway that is implicated in stress responses, assuming Trav3d-3 is modulated by or part of this pathway. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor, which could inhibit Trav3d-3 by targeting the Src family kinases that are involved in various signaling pathways, assuming Trav3d-3 is part of or regulated by these kinases. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which could inhibit Trav3d-3 by blocking the JNK signaling pathway that is involved in apoptosis and cellular differentiation, assuming Trav3d-3 is a component of or regulated by this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a PI3K inhibitor, which could inhibit Trav3d-3 by preventing PI3K-dependent signaling pathways, potentially involved in cell survival and growth, assuming Trav3d-3 is part of or regulated by PI3K signaling. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
PD173074 is an FGFR inhibitor, which could inhibit Trav3d-3 by blocking the fibroblast growth factor receptor signaling pathway, which plays a role in cell proliferation and differentiation, assuming Trav3d-3 is linked to this pathway. | ||||||